Lenvatinib

Description

Lenvatinib · CAS 417716-92-8 · C21H19ClN4O4. UNII EE083865G2. LogP: 3.3; Dissociation Constants: 5.05.

Identification

CAS Registry Number	417716-92-8
PubChem CID	9823820
Molecular formula	C21H19ClN4O4
IUPAC name	4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
UNII (FDA)	EE083865G2

Computed Descriptors

Molecular Weight	426.9
XLogP3	2.8
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	6
Exact Mass	426.1094828
Monoisotopic Mass	426.1094828
Topological Polar Surface Area	116
Heavy Atom Count	30
Formal Charge	0

Physical & Chemical Properties

LogP	3.3
Dissociation Constants	5.05

Physical description & handling notes

• Based on x-ray crystallography and kinetic interaction studies, lenvatinib binds to the adenosine 5'-triphosphate binding site of VEGFR2 and to a neighbouring region via a cyclopropane ring and thereby inhibits tyrosine kinase activity and associated signalling pathways.

GHS Hazard Classification

Reported hazard statements	H302 (50%), H315 (50%), H319 (50%), H335 (50%), H361 (50%)

Documented Uses

• Lenvatinib is indicated for the treatment of the following cancerous conditions: **Differentiated Thyroid Cancer (DTC)** - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer **Renal Cell Carcinoma (RCC)** - First-line treatment, in combination with [pembrolizumab], in adult patients with advanced renal cell carcinoma (RCC) - Treatment of advanced renal cell carcinoma, in combination with [everolimus], in adult patients who have previously tried ≥1
• Lenvatinib is a multiple receptor tyrosine kinase inhibitor demonstrating potent antiangiogenic properties indicated as monotherapy or combination therapy for certain malignancies. Lenvatinib is FDA-approved for radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), and advanced renal cell carcinoma (RCC).
• Lenvatinib is orally available multi-kinase inhibitor and antineoplastic agent that is used in treatment of advanced, metastatic medullary thyroid cancer and refractory renal cell carcinoma. Lenvatinib is associated with a modest rate of serum enzyme elevations during treatment and has been implicated to rare instances of clinically apparent, acute liver injury some of which have been fatal.
• Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors
• Avoid hypertensive herbs (e.g. bayberry, blue cohosh, cayenne, ephedra, and licorice). Lenvatinib may cause hypertension as an adverse effect; therefore, there may be additive blood pressure elevation when using hypertensive herbs.
• Take at the same time every day.

Synonyms

Lenvatinib; 417716-92-8; E7080; E-7080; E 7080; ER-203492-00; Kisplyx; 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; EE083865G2; CHEBI:85994; DTXSID50194605; 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide; 4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE; 6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-

Frequently Asked Questions

What are the CAS number and molecular formula of Lenvatinib?

CAS 417716-92-8; molecular formula C21H19ClN4O4; molecular weight — g/mol.

What other names is Lenvatinib known by?

Lenvatinib, 417716-92-8, E7080, E-7080, E 7080, ER-203492-00.

Is Lenvatinib classified as hazardous?

Hazard statements reported: H302, H315, H319, H335, H361.

What are the key physical properties of Lenvatinib?

LogP: 3.3; Dissociation Constants: 5.05.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.